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Breast tumours from BRCA1 and BRCA2 mutation
carriers are genetically instable and display specific
patterns of chromosomal aberrations, suggestive of
distinct genetic pathways in tumour progression. The
frequency of abnormalities aecting chromosome 17p
and the TP53 gene was determined in 27 breast tumours
from 26 female patients carrying the Icelandic BRCA2
founder mutation (999del5). Loss of heterozygosity
(LOH) was detected in 23 of the 27 tumours (85%).
The majority of tumours manifesting LOH had lost a
large region on 17p, although a more restricted loss,
including the TP53 locus was seen in a few tumours.
Positive p53 immunostaining was observed in 18 of 26
tumours (69%). However, mutations in the TP53 gene
were detected in only three tumours (11%), including a
missense (codon 139) and a nonsense mutation (codon
306) in two tumours with moderate p53 expression and a
frameshift deletion (codon 182) in a tumour with no
detectable p53 expression. Positive p53 immunostaining,
mainly weak, was observed in 16 of the 24 tumours
(66%) without TP53 mutation. The high frequency of
LOH at chromosome 17p13 suggests that one or more
genes from this region are involved in the development of
BRCA2-induced breast cancer. The frequent finding of
weak overexpression of, presumably wild type p53
protein, suggests an alternative mechanism of TP53
involvement specific to these tumours.
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Introduction
Breast cancer is one of the most common malignancies
in women living in the Western countries. About 5 –
10% of the cases are believed to be due to germline
mutations in breast cancer susceptibility genes (New-
man et al., 1988; Lynch et al., 1990). In the majority of
the families with multiple cases of breast cancer the
disease has been shown to be due to mutations in either
of the two tumour suppressor genes BRCA1 and
BRCA2 (Easton et al., 1993; Wooster et al., 1994).
Since mutations in the BRCA1 and BRCA2 genes are
rarely found in sporadic tumours (Futreal et al., 1994;
Teng et al., 1996) the question arises whether the
progression pathway of carcinogenesis may be dierent
in breast tumours in genetically predisposed individuals
and sporadic cases. A recent study using comparative
genomic hybridization (CGH) to evaluate genomic
changes in tumours from BRCA1 and BRCA2 carriers
showed a high incidence of genetic abnormalities in
these tumours (Tirkkonen et al., 1997). The tumours
from BRCA2 carriers showed a high frequency of
aberrations at many of the same chromosome regions
shown to be involved during sporadic tumour develop-
ment such as 13q, 1p, 3p, 6q, 8p, 11q, 17q22-q24, 17p,
18q and 20q13 but lower frequency at chromosomes
such as 7q and 16q. Chromosome 17p harbours the p53
gene. TP53 is considered to be a tumour suppressor
gene exerting growth-regulatory functions in response
to DNA damage by directly inhibiting DNA replication
(Soddu et al., 1996; Cox et al., 1995) or inducing
apoptosis (White, 1996; Levine 1997). Mutations in the
TP53 gene are among the most common genetic
alterations observed in human neoplasia (Hollstein et
al., 1991) and often result in the accumulation of a non-
functional protein (Iggo et al., 1990; Kastan et al., 1991;
Levine et al., 1991). TP53 mutations have been reported
in sporadic breast cancer and are in general associated
with adverse prognosis (Saitoh et al., 1994; Bergh et al.,
1995). In this paper genomic changes occurring at
chromosome 17p in tumours from BRCA2 carriers were
studied. We used microsatellite markers to map loss of
heterozygosity, and we evaluated the involvement of the
TP53 gene in the tumour progression by mutational
analysis of the gene and immunohistochemical staining
of the p53 protein. We also analysed the samples for
LOH at chromosome 13q12-q14, harbouring the
BRCA2 gene, and at chromosome 7q21-q35 which
according to the CGH results is rarely deleted in
BRCA2 tumours (Tirkkonen et al., 1997).
Results
Twenty-seven tumours from female breast cancer cases
with the 999del5 BRCA2 mutation were analysed.
Summarised in Table 1 are the results of the LOH
mapping with ten markers at 17p, the p53 immuno-
histochemical staining and the mutational analysis of
the TP53 gene. Clinico-pathological information is also
included, and data from the LOH analysis at
chromosomes 13q12-q14 and 7q21-q35 based on six
and nine markers, respectively. The two metastatic
tumours analysed (121ii and 123ii) showed the same
LOH and mutation pattern as the primary tumour (see
Table 1).
LOH analysis
We detected LOH at 17p13 with at least one marker in
23 of the 27 tumours analysed (85%). Twenty-one
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tumours showed LOH at the TP53 locus. In one
tumour (no. 124) LOH was detected at a region
telomeric to TP53, but not at the TP53 locus itself
(Figure 1a). In sample 123i LOH was detected at the
TP53 locus and not at other informative markers at
17p (Figure 1b).
Fifteen samples were analysed with markers at 7q21-
q35 and LOH at one or more markers was detected in
four tumours (27%). All but two of 23 samples
analysed showed LOH at the BRCA2 locus (91%).
Staining and mutational analysis of p53
Positive staining of the p53 protein was seen in 18 of
the 26 tumour samples (69%) available for analysis,
including one case (no. 126) diagnosed with in situ
Table 1 Patterns of allelic imbalance at chromosome 17p and the results of the immunohistochemical staining of p53
protein and mutation analysis of the TP53 gene. Also shown are the clinico-pathological factors determined for the tumours
and information on LOH at 13q12 – q14 and 7q21 – q35.a
aKey to the information in the Table: Solid boxes show LOH, open boxes show retention of heterozygosity and cross-
hatched boxes are homozygous for the given marker. Distances between markers according to Gyapay et al. (1994) are
shown in centimorgans (cM). a: bilateral case; ii: metastatic tumour from i; ND: not determined; ER: estrogen receptor
content: +=510 fmol/mg protein, 7=510 fmol/mg protein; PgR: progesterone receptor content: +=525 fmol/mg
protein, 7=525 fmol/mg protein; Node status: +=positive, 7=negative; grade: *lobular cancer; **in situ cancer; S-
phase: +=57%, 7=57%; Ploidy: +=aneuploid, 7=diploid; immunostaining: 7=negative, sca=scattered, +=weak,
++=moderate; LOH at 7q or 13q: +=loss of heterozygosity at one or more markers tested, 7=retention of
heterozygosity at all informative markers
Chromosome 17p13 and tumour development in BRCA2 mutations carriers
G Eiriksdottir et al
22
cancer. In 12 cases with positive staining where both
in situ and invasive tumour growth was seen, staining
was detected in cells of both components (Figure 2).
Four of the five tumours that did not show LOH at
the TP53 locus stained positively for the p53 protein
(Table 1). We used SSCP to look for TP53 mutations
and were able to identify band shifts in only four of
the tumours. A nucleotide deletion at codon 182
(TGC to GC), which leads to a frameshift mutation
and a premature translation termination (246ter), was
identified in one of the negatively staining tumours
(no. 121i), and the same mutation was detected in the
metastatic growth from this tumour (121ii). A
missense mutation at codon 139 (Lys to Asn) and a
nonsense mutation at codon 306 (Arg to Stop) were
observed in two tumours (nos. 111 and 112) with
positive immunostaining. The remaining SSCP-band
shift, observed in a tumour without detectable
staining, was found to be due to a known
polymorphism at codon 213 (CGA to CGG). The
same mutations have previously been detected in
studies of tumours from sporadic breast cancer
cases and are listed in the Human Gene Mutation
Database (Cardi, UWCM;http: //www.cf.ac.uk/
UWCM/mg/hgmdO.html).
Discussion
We have recently reported a high frequency of
genomic alterations, as seen by CGH analysis, in
breast tumours from both BRCA1 and BRCA2
mutation carriers (Tirkkonen et al., 1997). The CGH
results clearly suggested that the accumulation of
somatic genetic changes is not random and some
chromosome regions are aected more frequently than
others. The LOH results presented in this paper
support the CGH data, where the involvement of 7q
is seen in 27% of the tumours analysed versus 85%
and 91% at 17p and 13q respectively. The LOH
mapping results indicated the TP53 gene as a possible
target of the allelic deletions. This is supported by the
high number of tumours positively staining for the
p53 protein, taking into consideration the known
relationship between gene mutation and protein
accumulation (Iggo et al., 1990; Kastan et al., 1991;
Levine et al., 1991). However, TP53 mutations were
detected in only 11% of the tumours, suggesting the
involvement of alternative mechanisms that give rise
to (mainly weak), overexpression of wildtype p53. For
instance, the p53 protein is known to be modified and
stabilised by phosphorylation in response to DNA
damage and the action of DNA damage sensor
proteins (Kastan et al., 1992; Levine, 1997). One
cannot exclude the possibility that the deletions are
targeted to another gene on 17p as the majority of
tumours manifesting LOH had lost a large region
including the TP53 gene as well as markers
centromeric and, most often, telomeric to TP53. In
two cases (see 122, 123i and 123ii in Table 1) the
deletion pattern was in accordance with the specific
loss of TP53 or a closely located gene, while in one
tumour (no. 124) LOH was detected both telomeric
and centromeric to TP53 but not at the TP53 locus
itself. The existence of a tumour suppressor gene
telomeric to TP53 has been suggested previously
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Figure 1 Autoradiograms of PCR products with mocrosatellite
markers at 17p in matched normal (N) and tumour (T) breast
tissue of 999del5 BRCA2 carriers. (a) Sample 124 amplified with
markers TP53.15 and D17S796. Loss of heterozygosity is seen with
marker D17S796 and retention of heterozygosity with marker
TP53.15. (b) Sample 123i amplified with markers TP53.15 and
D17S945. Loss of heterozygosity is seen with marker TP53.15 and
retention of heterozygosity with marker D17S945
a
b
Figure 2 Immunohistochemical staining of p53 in breast tumour
tissue of a 999del5 BRCA2 carrier. Representative staining of tumour
sections in which in situ (a) and invasive tumour growth is seen (b)
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(Merlo et al., 1994; Cornelis et al., 1994) and cannot
be excluded as a target gene in these tumours.
It should be emphasised that in this study any
positive staining was judged to be significant and the
staining in all but one of these tumours was weak.
According to previously published studies disparity is
frequently encountered when correlating immunohis-
tochemical findings with DNA mutations of the TP53
gene (Jacquemier et al., 1994; Yandell and Thor,
1993), especially regarding samples with weak staining
(Gretarsdottir et al., 1996; Hall and Lane, 1994).
Possible explanations for the positive staining of p53
in the 16 cases where no TP53 mutations were
detected are that the protein expression was caused by
mutations in another gene that prolongs the half-life
of the p53 protein, by mutations that were not
detected by SSCP due to co-migration of wild-type
and mutant alleles, by mutations in exons other than
those screened in this study by SSCP or by mutations
that were not detected due to a dilution factor of
normal cells. The two last explanations are not very
likely since relatively few mutations of the TP53 gene
have been found to occur outside the exons tested in
this study (Saitoh et al., 1994; Sjo¨gren et al., 1996)
and contamination of the tumours by normal cells is
not large as LOH was detected in 91% of the
samples.
The high frequency of positive staining of p53 in the
tumours of BRCA2 carriers determined here is
comparable to what has been reported earlier for
BRCA1 tumours (Johannsson et al., 1997; Sobol et al.,
1997) and higher than reported in similar studies on
sporadic breast cancer (Gretarsdottir et al., 1996;
Cornelis et al., 1994; Runnebaum et al., 1991). In
agreement with results of histopathological studies
showing BRCA2 tumours to be of significantly higher
grade than sporadic tumours (Marcus et al., 1996;
Lakhani et al., 1997), most of the tumours in this study
are grade II and III. A significant association between
p53 abnormalities and higher histological grade has
been shown in sporadic tumours (Gretarsdottir et al.,
1996; Umekita et al., 1994; Bhargava et al., 1994). In
this study no association was seen between p53
aberrations and histological grade or the other
recognised prognostic factors listed in Table 1. In 12
cases where both in situ and invasive tumour growth
was seen, staining was detected in cells of both
components. Staining was also seen in the tumour
cells of one case (no. 126) diagnosed with in situ
cancer.
The interaction recently suggested between the
BRCA proteins and Rad51 protein in meiotic and
mitotic recombination and DNA repair (Scully et al.,
1997; Sharan et al., 1997), is in accordance with a role
of BRCA2 and BRCA1 in preservation of genome
integrity. Thus, cells without BRCA1 or BRCA2
activity might be defective in the repair of lesions
such as DNA double-strand breaks (Scully et al., 1997;
Sharan et al., 1997). In order to tolerate and survive
with such DNA damage, cells must also acquire a
deregulation in growth arrest and apoptosis. The
results of the present study indicate that at an early
stage in the development of BRCA2 predisposed
tumours the p53 pathway is activated, and at some
point either bypassed or inactivated by an unknown
mechanism.
Materials and methods
Patients and tumour material
Screening of 459 randomly chosen breast cancer cases
diagnosed in the years 1989 – 1994 revealed 39 female
patients with the 999del5 BRCA2 mutation (Johannes-
dottir et al., 1996). Paired blood and tumour DNA were
available from 27 primary breast tumours from 26 females
(one bilateral case). These tumours were removed from
the patients prior to any treatment. Two metastatic
tumours were also available from 999del5 BRCA2
mutation carriers. Conventional methods were used for
DNA extraction from blood and tumour material. The
samples were subjected to PCR analysis using Dyna-
ZymeTM polymerase (Finnzymes Oy, Espoo, Finland) in
the buer solution provided by the manufacturer. The
TP53.15 marker, described by Jones and Nakamura (1992)
and mapping within the TP53 gene, was obtained from
Pharmacia Biotech (Denmark). All the other markers were
obtained from Research Genetics (Huntsville, AL);
D17S926, D17S796, D17S945, D17S947, D17S921,
D17S953, D17S925, D17S798, D17S933, D13S283,
D13S1246, D13S260, D13S171, D13S267, D13S263,
D7S492, D7S518, D7S515, D7S501, D7S523, D7S471,
D7S522, D7S480, D7S500. PCR products were subjected
to 6.5% acrylamide denaturing gels and detected by the
method of Vignal et al. (1993). Autoradiograms were
inspected visually by three independent viewers, compar-
ing the intensity of alleles from normal and tumour DNA.
Any absence or significant decrease of one allele relative
to the other was considered loss of heterozygosity (LOH).
Relevant information regarding pathological factors of the
tumours was recorded by pathologists at our department.
Tumour grade was assessed by a modified Bloom-
Richardson system (Elston, 1987). Estrogen- and proges-
terone-receptors (ER and PgR) were analysed using a
ligand binding assay. S-phase fraction and DNA-ploidy
were analysed using a FACScan flow cytometer (Becton-
Dickinson) utilising paran embedded tissue. The Fisher’s
exact test (Abacus Concepts, Survival Tools for StatView,
Berkeley, CA) was used to assess the relationship between
p53 staining and/or TP53 mutations and clinico-patholo-
gical factors.
Mutation and sequencing analysis
The PCR amplification and SSCP conditions for exons 5 –
9 are described by El-Naggar et al. (1995), and for exon 4
by Deng et al. (1994). PCR products were diluted 1 : 4 in
95% formamide, 10 mM NaOH, 0.025% xylene cyanol
and 0.025% bromophenol blue and denatured at 958C for
8 – 10 min. The mixture was applied to 0.56MDE
(Mutation Detection Enhancement, AT Biochem, no 1-
500-01), 0.66TBE gels with or without 5 or 10% glycerol.
The gels without glycerol and the 5% glycerol gels were
run at 30 W for 6 – 10 h at room temperature; the 10%
glycerol gels were run at 48C for 4 h. The PCR products
were detected with the same non-radioactive method as
used for the microsatellite markers mentioned above.
Samples positive in the SSCP analysis were subjected to
a new PCR reaction with a biotinylated reverse primer
and solid phase sequencing was carried out. The PCR
products were immobilized on streptavadin beads (M-280;
Dynal) and denatured with alkaline. The single-stranded
biotinylated DNA template was sequenced using Seque-
nase 2.0 and [a-33P]dATP (Amersham, Buckinghamshire,
England).
Immunohistochemistry
Immunohistochemical staining of the p53 protein was
performed with a commercially available antibody (clone
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D07, Novocastra Laboratories, Newcastle upon Tyne, UK)
utilizing formalin fixed 4m paran sections. This antibody
recognizes both mutant and wild type p53. Sections were
pretreated in an 850 watt microwave oven in citrate buer
at pH 6.0 for 265 min at full power. The sections were
incubated with the primary antibody for 30 min at a 1 : 50
dilution and subsequently incubated with a second goat
anti-mouse biotinylated antibody (Dako, Glostrup, Den-
mark) for 30 min before being reacted with a streptavadin-
biotin-peroxidase complex (Dako) for 30 min (DAKO,
Glostrup, Denmark). Diaminobenzidine tetrahydrochloride
was used as chromogen to detect the peroxidase activity.
Results were scored according to the method of Fisher et
al. (1994). In brief, strong staining is classified as dark
nuclear staining in 450% of cells; moderate staining is
dark staining in 550% of cells or moderate staining in
450% of cells; and weak staining is moderate staining in
550% of cells or pale staining in any proportion of cells.
Scattered staining is dark nuclear staining in widely
scattered cells.
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